| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 21.19▼ | 21.23▼ | 21.35▼ | 21.79▼ | 21.89▼ |
| MA10 | 21.14▼ | 21.49▼ | 21.61▼ | 21.57▼ | 23.97▼ |
| MA20 | 21.17▼ | 21.66▼ | 21.87▼ | 22.01▼ | 23.90▼ |
| MA50 | 21.51▼ | 21.93▼ | 21.66▼ | 24.35▼ | 23.65▼ |
| MA100 | 21.66▼ | 21.63▼ | 21.71▼ | 23.98▼ | 23.95▼ |
| MA200 | 21.89▼ | 21.78▼ | 22.72▼ | 24.57▼ | 36.05▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.023▲ | -0.079▼ | -0.126▼ | 0.101▲ | -0.561▼ |
| RSI | 42.208▼ | 35.476▼ | 38.745▼ | 35.904▼ | 38.084▼ |
| STOCH | 38.225 | 25.438 | 28.743 | 57.005 | 21.601 |
| WILL %R | -76.724▼ | -87.204▼ | -91.667▼ | -62.832 | -83.846▼ |
| CCI | -37.055 | -112.997▼ | -158.565▼ | -73.459 | -113.526▼ |
|
Thursday, November 06, 2025 09:13 PM
Pacira BioSciences Inc (PCRX) reports a 6% revenue increase, improved gross margins, and strategic advancements in its clinical pipeline.
|
|
Thursday, November 06, 2025 02:42 PM
Third quarter revenues up 6% driven by EXPAREL volume growth of 9% ---- Several key milestones advance 5x30 path to growth and value creation ...
|
|
Thursday, November 06, 2025 04:50 AM
Pacira BioSciences (PCRX) faces Exparel generic threats in 2024. Learn about risks, portfolio strategy shifts, and key milestones to watch.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 06/11/25 | 21.83 | 21.98 | 20.64 | 21.10 | 980,653 |
| 05/11/25 | 22.60 | 22.70 | 21.605 | 21.85 | 672,139 |
| 04/11/25 | 21.78 | 22.61 | 21.20 | 22.44 | 1,032,399 |
| 03/11/25 | 21.37 | 22.74 | 21.37 | 22.19 | 1,400,332 |
| 31/10/25 | 21.27 | 21.775 | 20.96 | 21.38 | 831,237 |
| 30/10/25 | 21.05 | 21.72 | 20.70 | 21.27 | 371,346 |
| 29/10/25 | 21.17 | 21.46 | 20.85 | 21.01 | 424,879 |
| 28/10/25 | 21.595 | 21.595 | 20.98 | 21.36 | 267,526 |
| 27/10/25 | 21.83 | 21.85 | 20.50 | 21.33 | 623,147 |
| 24/10/25 | 21.61 | 21.90 | 21.52 | 21.74 | 298,954 |
|
|
||||
|
|
||||
|
|